Literature DB >> 19541356

Phenotype of atopic dermatitis subjects with a history of eczema herpeticum.

Lisa A Beck1, Mark Boguniewicz, Tissa Hata, Lynda C Schneider, Jon Hanifin, Rich Gallo, Amy S Paller, Susi Lieff, Jamie Reese, Daniel Zaccaro, Henry Milgrom, Kathleen C Barnes, Donald Y M Leung.   

Abstract

BACKGROUND: A subset of subjects with atopic dermatitis (AD) are susceptible to serious infections with herpes simplex virus, called eczema herpeticum, or vaccina virus, called eczema vaccinatum.
OBJECTIVE: This National Institute of Allergy and Infectious Diseases-funded multicenter study was performed to establish a database of clinical information and biologic samples on subjects with AD with and without a history of eczema herpeticum (ADEH(+) and ADEH(-) subjects, respectively) and healthy control subjects. Careful phenotyping of AD subsets might suggest mechanisms responsible for disseminated viral infections and help identify at-risk individuals.
METHODS: We analyzed the data from 901 subjects (ADEH(+) subjects, n = 134; ADEH(-) subjects, n = 419; healthy control subjects, n = 348) enrolled between May 11, 2006, and September 16, 2008, at 7 US medical centers.
RESULTS: ADEH(+) subjects had more severe disease based on scoring systems (Eczema Area and Severity Index and Rajka-Langeland score), body surface area affected, and biomarkers (circulating eosinophil counts and serum IgE, thymus and activation-regulated chemokine, and cutaneous T cell-attracting chemokine) than ADEH(-) subjects (P < .001). ADEH(+) subjects were also more likely to have a history of food allergy (69% vs 40%, P < .001) or asthma (64% vs 44%, P < .001) and were more commonly sensitized to many common allergens (P < .001). Cutaneous infections with Staphylococcus aureus or molluscum contagiosum virus were more common in ADEH(+) subjects (78% and 8%, respectively) than in ADEH(-) subjects (29% and 2%, respectively; P < .001).
CONCLUSION: Subjects with AD in whom eczema herpeticum develops have more severe T(H)2-polarized disease with greater allergen sensitization and more commonly have a history of food allergy, asthma, or both. They are also much more likely to experience cutaneous infections with S. aureus or molluscum contagiosum.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19541356      PMCID: PMC3056058          DOI: 10.1016/j.jaci.2009.05.020

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  37 in total

1.  Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey.

Authors:  Samuel J Arbes; Peter J Gergen; Leslie Elliott; Darryl C Zeldin
Journal:  J Allergy Clin Immunol       Date:  2005-08       Impact factor: 10.793

2.  Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss Study on Air Pollution and Lung Diseases in Adults.

Authors:  J M Tschopp; D Sistek; C Schindler; P Leuenberger; A P Perruchoud; B Wüthrich; M Brutsche; J P Zellweger; W Karrer; O Brändli
Journal:  Allergy       Date:  1998-06       Impact factor: 13.146

3.  Prevalence of IgE-mediated food allergy among children with atopic dermatitis.

Authors:  P A Eigenmann; S H Sicherer; T A Borkowski; B A Cohen; H A Sampson
Journal:  Pediatrics       Date:  1998-03       Impact factor: 7.124

4.  Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate.

Authors:  H Kimata
Journal:  Ann Allergy Asthma Immunol       Date:  1999-03       Impact factor: 6.347

5.  Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity.

Authors:  Y Jerold Gordon; Ling C Huang; Eric G Romanowski; Kathleen A Yates; Rita J Proske; Alison M McDermott
Journal:  Curr Eye Res       Date:  2005-05       Impact factor: 2.424

6.  IgE levels, atopy markers and hay fever in relation to age, sex and smoking status in a normal adult Swiss population. SAPALDIA (Swiss Study on Air Pollution and Lung Diseases in Adults) Team.

Authors:  B Wüthrich; C Schindler; T C Medici; J P Zellweger; P Leuenberger
Journal:  Int Arch Allergy Immunol       Date:  1996-12       Impact factor: 2.749

7.  The use of Phadiatop in mass-screening programmes of inhalant allergies: advantages and limitations.

Authors:  P M Matricardi; R Nisini; J G Pizzolo; R D'Amelio
Journal:  Clin Exp Allergy       Date:  1990-03       Impact factor: 5.018

8.  Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis.

Authors:  Q Hamid; M Boguniewicz; D Y Leung
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

9.  Increasing incidence of eczema herpeticum: analysis of seventy-five cases.

Authors:  K Bork; W Bräuninger
Journal:  J Am Acad Dermatol       Date:  1988-12       Impact factor: 11.527

10.  Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6.

Authors:  Byung Eui Kim; Donald Y M Leung; Mark Boguniewicz; Michael D Howell
Journal:  Clin Immunol       Date:  2007-12-31       Impact factor: 3.969

View more
  83 in total

1.  Susceptibility to vaccinia virus infection and spread in mice is determined by age at infection, allergen sensitization and mast cell status.

Authors:  Joanne Domenico; Joseph J Lucas; Mayumi Fujita; Erwin W Gelfand
Journal:  Int Arch Allergy Immunol       Date:  2012-01-26       Impact factor: 2.749

2.  Identification of novel gene signatures in patients with atopic dermatitis complicated by eczema herpeticum.

Authors:  Lianghua Bin; Michael G Edwards; Ryan Heiser; Joanne E Streib; Brittany Richers; Clifton F Hall; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2014-08-23       Impact factor: 10.793

3.  Comorbidity in Atopic Dermatitis.

Authors:  Eric L Simpson
Journal:  Curr Dermatol Rep       Date:  2012-03-01

4.  Thymic stromal lymphopoietin variation, filaggrin loss of function, and the persistence of atopic dermatitis.

Authors:  David J Margolis; Brian Kim; Andrea J Apter; Jayanta Gupta; Ole Hoffstad; Maryte Papadopoulos; Nandita Mitra
Journal:  JAMA Dermatol       Date:  2014-03       Impact factor: 10.282

5.  A corneal dendritic lesion with a skin eruption: eczema herpeticum, an important differential diagnosis.

Authors:  Alex Steptoe; Tafadzwa Young-Zvandasara; Mohammed Muhtaseb
Journal:  BMJ Case Rep       Date:  2015-01-30

6.  Reductions in claudin-1 may enhance susceptibility to herpes simplex virus 1 infections in atopic dermatitis.

Authors:  Anna De Benedetto; Mark K Slifka; Nicholas M Rafaels; I-Hsin Kuo; Steve N Georas; Mark Boguniewicz; Tissa Hata; Lynda C Schneider; Jon M Hanifin; Richard L Gallo; David C Johnson; Kathleen C Barnes; Donald Y M Leung; Lisa A Beck
Journal:  J Allergy Clin Immunol       Date:  2011-04-13       Impact factor: 10.793

7.  Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults.

Authors:  Shanthi Narla; Jonathan I Silverberg
Journal:  Ann Allergy Asthma Immunol       Date:  2018-01       Impact factor: 6.347

Review 8.  The importance of TSLP in allergic disease and its role as a potential therapeutic target.

Authors:  Antonella Cianferoni; Jonathan Spergel
Journal:  Expert Rev Clin Immunol       Date:  2014-11       Impact factor: 4.473

9.  Defective natural killer cell activity in a mouse model of eczema herpeticum.

Authors:  Yuko Kawakami; Tomoaki Ando; Jong-Rok Lee; Gisen Kim; Yu Kawakami; Tae Nakasaki; Manando Nakasaki; Kenji Matsumoto; Youn Soo Choi; Toshiaki Kawakami
Journal:  J Allergy Clin Immunol       Date:  2016-07-29       Impact factor: 10.793

10.  High-intensity swimming exercise increases dust mite extract and 1-chloro-2,4-dinitrobenzene-derived atopic dermatitis in BALB/c mice.

Authors:  Sang-Hyun Kim; Eun-Kyung Kim; Eun-Ju Choi
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.